Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27710


Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab. Secondary Objectives: To evaluate safety & tolerability of erlotinib + bevacizumab among pts w recurrent malignant gliomas To evaluate radiographic response of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab To evaluate pharmacokinetics of erlotinib when administered to pts w recurrent malignant gliomas; & to examine relationship of clinical response to EGFR expression, amplification, & v-III mutation, PTEN expression, VEGF expression & phosphorylated PKB/Akt in archival tumor samples

Study summary:

Exploratory, ph II study designed to assess anti-tumor activity of combinatorial regimen consisting of erlotinib + bevacizumab among pts w recurrent malignant glioma. Signal transduction inhibitors, such as erlotinib, as well as anti-angiogenic agents, such as bevacizumab, are expected to exert a cytostatic anti-tumor effect. Primary endpoint of study is probability of progression-free survival at 6 months. An important secondary objective is to further assess the safety of erlotinib + bevacizumab for pts w RMG. Pharmacokinetic studies included in protocol will evaluate impact of EIAEDs on metabolism of erlotinib. If study demonstrates that combo regimen of erlotinib + bevacizumab is associated w encouraging anti-tumor activity among pts w RMG, further assessment of regimen in additional ph II & possibly ph III studies, will be considered.


Inclusion Criteria: - Pts have histologically confirmed diagnosis of recurrent/progressive WHO gr III & IV MG & meet following inclusion criteria: - Age >18 yrs - Interval of >4 wks since prior surgery - Interval of >4 wks since prior XRT or chemo, unless there is unequivocal evidence of progressive disease & pts have recovered from all anticipated toxicity of most recent therapy - Karnofsky performance status score >60 - Hematocrit > 29 percent, ANC >1,500 cells/microliter, platelets >100,000 cells/microliter - Serum creatinine <.5mg/dl, BUN <25 mg/dl, serum SGOT & bilirubin <1.5 x ULN - For pts on corticosteroids, they have been on stable dose for 1 wk prior to entry - Pts have had prior bevacizumab are eligible however interval of >6 wks must have elapsed since their last dose - Signed informed consent approved by IRB prior to patient entry; - If sexually active, pts must agree to take contraceptive measures for duration of treatments Exclusion Criteria: - Prior therapy w either bevacizumab/EGFR-directed agents - >3 prior recurrences - Pregnancy/breast feeding - Co-medication w immuno-suppressive agents other than corticosteroids including but not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil - Evidence of CNS hemorrhage on baseline MRI on CT scan - Pts who require therapeutic anti-coagulation - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics & psychiatric illness/social situations that would limit compliance w study requirements, or disorders associated w significant immunocompromised state - Pts w another primary malignancy that has required treatment within past year - Pts w acute/chronic renal insufficiency/those w acute renal insufficiency of any severity due to hepato-renal syndrome/in peri-operative liver transplantation period



Primary Contact:

Principal Investigator
David A. Reardon, MD
Duke University Health System

Backup Contact:


Location Contact:

Durham, North Carolina 27710
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.